Clinical retrospective analysis of 64 patients with hemophilia in 5 recent years in Anshan
YAN Chao-qi1 LENG Qing1 YOU Guo-ping2 ZHANG Li-jun3▲
1.Department of Hematology,Central Hospital of Anshan City in Liaoning Province,Anshan 114000,China;2.Department of Hematology,Anshan Hospital,the First Affiliated Hospital of China Medical University,Anshan City,Liaoning Province,Anshan 114000,China;3.Department of Hematology,the First Affiliated Hospital of China Medical University,Shenyang City,Liaoning Province,Shenyang 110000,China
Abstract：Objective To analyze the clinical features,diagnostic age and replacement therapy pattern of patients with hemophiliain in Anshan.Methods The clinical data of 64 patients with hemophilia treated in Anshan Hospital,the First Affiliated Hospital of China Medical University from January 2013 to January 2018 were retrospective analyzed.Results All patients were male,47 patients had been treated in hospital,43 cases had hemophilia A and 4 cases had hemophilia B.27 patients(57.45%)had family history of hemophilia.The median age of the first diagnosed was 5 years old.The diagnostic timing was related to the severity of the first hemorrhage(P＝0.0033).18 cases(38.30%)of the hospitalized patients had different degree of joint deformity.Most of the registered patients were treated on demand.There was no strict preventive treatment.Conclusion There are 64 cases of hemophilia in Anshan.The diagnosis age is delayed and the replacement therapy is not enough.The timing of diagnosis is related to the degree of first bleeding,and the incidence of joint deformity is high.
闫朝奇;冷青;由国平;张丽君. 鞍山地区2013年1月～2018年1月血友病诊疗的临床回顾分析[J]. 中国当代医药, 2018, 25(21): 158-160.
YAN Chao-qi;LENG Qing;YOU Guo-ping;ZHANG Li-jun. Clinical retrospective analysis of 64 patients with hemophilia in 5 recent years in Anshan. 中国当代医药, 2018, 25(21): 158-160.
Barrowcliffe TW.Standardization of FⅧ &FⅨ assays[J].Haemophilia，2003 ，9（4）：397-402.
[4]
Gouw SC，van den Berg HM，Oldenburg J，et al.F8 gene mutation type and inhibitor development in patients with severe hemophilia A：systematic review and meta-analysis[J].Blood，2012，119（12）：2922-2934.
[5]
Fischer K，Collins P，Bjorkman S，et al.Trends in bleeding patterns during prophylaxis for severe haemophilia：observations from a series of prospective clinical trials[J].Haemophilia，2011，17（3）：433-438.
[6]
Di Minno MN，Ambrosino P，Franchini M，et al.Arthropathy in patients with moderate hemophilia A：a systematic review of the literature[J].Semin Thromb Hemost，2013，39（7）：723-731.
[11]
Saenko EL，Pipe SW.Strategies towards a longer acting factorⅧ[J].Haemophilia，2006，12（Suppl 3）：42-51
[12]
SpencerHT，RileyBE，DoeringCB.Stateoftheart：genetherapy of haemophilia[J].Haemophilia，2016，22（Suppl 5）：66-71.
[15]
Davidoff AM，Nathwani AC.Genetic targeting of the albumin locus to treat hemophilia[J].N Engl J Med，2016，374（13）：1288-1290.
[7]
Manco-Johnson MJ，Abshire TC，Shapiro AD，et al.Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia[J].N Engl J Med，2007，357（6）：535-544.
[8]
Mahlangu J，Powell JS，Ragni MV，et al.Phase 3 study of recombinant factorⅧFc fusion protein in severe hemophilia A[J].Blood，2014，123（3）：317-325.
[9]
Martinowitz U，Lissitchkov T，Lubetsky A，et al.Results of aphase Ⅰ/Ⅱ open-label，safety and effi cacy trial of coagulation factor Ⅸ （recombinant），albumin fusion protein in haemophilia bpatients[J].Haemophilia，2015，21（6）：784-790.
[10]
Ingerslev J，Sorensen B.Parallel use of bypassing agents in haemophilia with inhibitors：a critical review[J].Br J Haematol，2011，155（2）：256-262.
[13]
Fomin ME，Togarrati PP，Muench MO.Progress and challenges in the development of a cell-based therapy for hemophilia A[J].J Thromb Haemost，2014，12（12）：1954-1965.
[14]
Guan Y，Ma Y，Li Q，et al.CRISPR/Cas9-mediated somatic correction of a novel coagulator factorⅨgene mutation ameliorates hemophilia in mouse[J].EMBO Mol Med 2016，8（5）：477-488.
京公网安备 11010502046607号